Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
CEFUROXIME SODIUM (UNII: R8A7M9MY61) (CEFUROXIME - UNII:O1R9FJ93ED)
Hikma Pharmaceuticals USA Inc.
CEFUROXIME SODIUM
CEFUROXIME 750 mg
INTRAMUSCULAR
PRESCRIPTION DRUG
Cefuroxime for Injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - Lower Respiratory Tract Infections , including pneumonia, caused by Streptococcus pneumoniae , Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . - Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. - Skin and Skin-Structure Infections caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli , Klebsiella spp., and Enterobacter spp. - Septicemia caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. - Mening
Cefuroxime for Injection, USP in the dry state should be stored at 20-25° (68-77°F) [see USP Controlled Room Temperature] and protected from light. Cefuroxime for Injection, USP, is a dry, white to off-white powder supplied as follows: NDC 0143-9568-25 Sterile Cefuroxime Sodium USP, 750 mg Carton of 25 Equivalent to Cefuroxime, IM/IV Injection NDC 0143-9567-25 Sterile Cefuroxime Sodium USP, 1.5 grams Carton of 25 Equivalent to Cefuroxime, IV Injection Also available as: NDC 0143-9569-10 Sterile Cefuroxime Sodium USP, 7.5 grams Carton of 10 Equivalent to Cefuroxime, Pharmacy Bulk Package
Abbreviated New Drug Application
CEFUROXIME- CEFUROXIME INJECTION, POWDER, FOR SOLUTION WEST-WARD PHARMACEUTICALS CORP ---------- CEFUROXIME FOR INJECTION, USP Rx ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection and other antibacterial drugs, Cefuroxime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Cefuroxime is a sterile semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2- yl)acetamido]ceph-3-em-4-carboxylate, and it has the following structural formula: The molecular formula is C H N NaO S, representing a molecular weight of 446.4. Cefuroxime for Injection, USP contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity. Cefuroxime for Injection, USP in sterile crystalline form is supplied in vials equivalent to 750 mg or 1.5 g of cefuroxime as cefuroxime sodium. Solutions of Cefuroxime for Injection, USP range in color from light yellow to amber, depending on the concentration and diluent used. The pH of freshly constituted solutions usually ranges from 6 to 8.5. CLINICAL PHARMACOLOGY After intramuscular (IM) injection of a 750-mg dose of cefuroxime to normal volunteers, the mean peak serum concentration was 27 mcg/mL. The peak occurred at approximately 45 minutes (range, 15 to 60 minutes). Following IV doses of 750 mg and 1.5 grams, serum concentrations were approximately 50 and 100 mcg/mL, respectively, at 15 minutes. Therapeutic serum concentrations of approximately 2 mcg/mL or more were maintained for 5.3 hours and 8 hours or more, respectively. There was no evidence of accumulation of cefuroxime in the serum following IV administration of 1.5-g doses every 8 hours to normal volunteers. The serum half-life after either IM or IV injections is approximately 80 minutes. Approximately 89% of a dose of cefuroxime is excreted by the kidneys over read_full_document